Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison

References

• Steg PG, Hellkamp A, Angiolillo DJ, Ardissino D, Katus HA, Harrington RA, Himmelmann A, Maya J, Meier B, Schulte PJ, Storey RF, Wallentin L, James SK, on behalf of the PLATO Investigators. Ticagrelor vs Clopidogrel among STEMI patients undergoing primary PCI within 12 hours of admission. www.crf.org/pdf/meetings/tct/2014/TCT_2014_program.pdf. Accessed 3 October 2015.
   Google Scholar
• Alexopoulos D, Xanthopoulou I, Deftereos S, Sitafidis G, Kanakakis I, Hamilos M, Angelidis C, Petousis S, Stakos D, Parissis H, Vavouranakis M, Davlouros P, Goudevenos J, Stefanadis C. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Prevalence, predictors and short-term outcome. Am Heart J 2014;167:68–76.
   PubMed Web of Science ®Google Scholar
• Heestermans AA, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, Schömig E, Verheugt FW, ten Berg JM. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008;122:776–781.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Theodoropoulos KC, Stavrou EF, Xanthopoulou I, Kassimis G, Tsigkas G, Damelou A, Davlouros P, Hahalis G, Athanassiadou A. Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. Cardiovasc Drugs Ther 2012;26:393–400.
   PubMed Web of Science ®Google Scholar
• Biscaglia S, Tebaldi M, Vranckx P, Campo G, Valgimigli M. Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention. J Thromb Haemost 2013;11:192–194.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797–804.
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601–1606.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Gkizas V, Patsilinakos S, Xanthopoulou I, Angelidis C, Anthopoulos P, Makris G, Perperis A, Karanikas S, Koutsogiannis N, Davlouros P, Deftereos S, Chiladakis J, Hahalis G. Double vs standard loading dose of ticagrelor: Onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol 2013;62:940.
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010;56:1456–1462.
   PubMed Web of Science ®Google Scholar
• Hibbert B, Maze R, Pourdjabbar A, Simard T, Ramirez FD, Moudgil R, Blondeau M, Labinaz M, Dick A, Glover C, Froeschl M, Marquis JF, So DY, Le May MR. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: The CAPITAL RELOAD study. PLoS One 2014;9:e92078.
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569–2619.
   Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2013;61:e78–140.
   PubMed Web of Science ®Google Scholar
• Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 as say: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124:1132–1137.
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: The first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259–274.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study. Circulation 2010;121:1188–1199.
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852–1856.
   PubMed Web of Science ®Google Scholar
• Nührenberg TG, Trenk D, Leggewie S, Ristau I, Amann M, Stratz C, Hochholzer W, Valina CM, Neumann FJ. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: Platelet reactivity in an observational study. Platelets 2013;24:549–553.
   PubMed Web of Science ®Google Scholar
• Mangiacapra F, Patti G, Barbato E, Orlic D, Peace AJ, D’Ambrosio A, Ostojic M, Wijns W, Di Sciascio G. Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: An analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) study. Int J Cardiol 2012;160:213–214.
   PubMed Web of Science ®Google Scholar
• Patti G, Bárczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V, Barbato E, Merkely B, Edes I, Ostojic M, Wijns W, Di Sciascio G. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 2011;58:1592–1599.
   PubMed Web of Science ®Google Scholar
• Montalescot G, van’t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW; ATLANTIC Investigators. ATLANTIC Investigators. Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. N Engl J Med 2014;371:1016–1027.
   Google Scholar
• Clemmensen P, Grieco N, Ince H, Danchin N, Goedicke J, Ramos Y, Schmitt J, Goldstein P; on behalf of the MULTIPRAC study investigators. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel – the European MULTIPRAC Registry. Eur Heart J Acute Cardiovasc Care 2015;4:220–229.
   Google Scholar
• DiNicolantonio JJ, Serebruany VL. Exploring the reduction in myocardial infarctions in the PLATO trial: Which patients benefited on ticagrelor vs. clopidogrel? Int J Cardiol 2013;165:396–397.
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Siha H, Fu Y, Westerhout CM, Steg PG, James SK, Storey RF, Horrow J, Katus H, Clemmensen P, Harrington RA, Wallentin L. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: Insights from the ECG substudy. Circulation 2012;125:514–521.
   PubMed Web of Science ®Google Scholar
• Winter JL, Lindefjeld DS, Veas N, Guarda E, Valdebenito M, Méndez M, Pérez O, Zuanic K, Mestas M, Martínez A. Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMI-TICLO trial). Cardiovasc Revasc Med 2014;15:284–288.
   PubMedGoogle Scholar